The use of clonidine in the treatment of nightmares among patients with co-morbid PTSD and traumatic brain injury

International Journal of Psychiatry in Medicine

Volumn 44, Issue 2, 2012, Pages 165-169

  Alao, Adekola ^a   Selvarajah, Jennifer ^a   Razi, Syed ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Clonidine; Nightmares; Norepinephrine; PTSD; Traumatic brain injury

Indexed keywords

CITALOPRAM; CLONAZEPAM; CLONIDINE; OLANZAPINE; PRAZOSIN; VENLAFAXINE;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; COGNITIVE THERAPY; COMORBIDITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; HUMAN; MALE; NIGHTMARE; POSTTRAUMATIC STRESS DISORDER; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; VETERAN;

ADULT; BRAIN INJURIES; CLONIDINE; COMBAT DISORDERS; DREAMS; HUMANS; MALE; MIDDLE AGED; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; VETERANS;

EID: 84870907784     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.44.2.g     Document Type: Article

References (10)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author, 2000.
2. Wells TS, Miller SC, Adler AB, Engel CC, Smith TC, Fairbank JA. Mental health impact of the Iraq and Afghanistan conflicts: A review of US research, service provision, and programmatic responses. International Review of Psychiatry 2011; 23(2): 144-152.
3. Yehuda R, Siever LJ, Teicher MH, Levengood RA, Gerbe DK, Schmeidler J, et al. Plasma norepinepherine and 3-methyoxy-4hydroxyphenylglycol concentration and severity of depression in PTSD and major depressive disorder. Biology and Psychiatry 1998:44: 56-63.
4. Dêbiec J, Bush DE, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats - A possible mechanism for the persistence of traumatic memories in PTSD. Depression and Anxiety 2011; 28(3): 186-193.
5. Mellman TA, Kumar A, Kulick-Bell R, Kumar M, Nolan B. Nocturnal/daytime urine noradrenergic measures and sleep in combat-related PTSD. Biology and Psychiatry 1995; 38(3): 174-179.
6. Geracioti TD Jr, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck PE Jr, Kasckow JW. CSF norepinephrine concentrations in posttraumatic stress disorder. American Journal of Psychiatry 2001; 158(8): 1227-1230.
7. Pervanidou P, Chrousos GP. Neuroendocrinology of post-traumatic stress disorder. Progress in Brain Research 2010; 182: 149-160.
8. Pitman RK, Delahanty DL, et al. Conceptually driven pharmacologic approaches to acute trauma. CNS Spectrum 2005; 10(2): 99-106.
9. Aurora RN, Zak RS, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, Maganti RK, Ramar K, Kristo DA, Bista SR, Lamm CI, Morgenthaler TI, Standards of Practice Committee, American Academy of Sleep Medicine. Best practice guide for the treatment of nightmare disorder in adults. Journal of Clinical Sleep Medicine 2010; 6(4): 389-401.
10. Byers MG, Allison KM, Wendel CS, Lee JK. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: An assessment of long-term comparative effectiveness and safety. Journal of Clinical Psychopharmacology 2010; 30(3): 225-229.